Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Updated: Multiple Biosimilars To Avastin Have Launched In EU

Industry Had Expected June Roll-Out

Executive Summary

Roche’s biggest seller, Avastin, has fallen to biosimilar competition in Europe, with at least one company confirming launch to Generics Bulletin.

You may also be interested in...



Celltrion To Jostle For Space In Crowded EU Bevacizumab Market

The European Commission has approved Vegzelma, a bevacizumab biosimilar developed by South Korean biopharma giant Celltrion. Vegzelma joins nine other bevacizumab biosimilar marketing authorization applications approved in the EU, promising to intensify price competition for the  critical late-stage cancer treatment.

Celltrion Gets Ready To Face The Competition After European Bevacizumab Nod

Celltrion has received a positive opinion from the EMA’s CHMP for its Vegzelma bevacizumab biosimilar rival to Avastin, setting up the Korean firm to enter a competitive European market that already includes several bevacizumab biosimilars.

Amgen Optimistic Over Inflammation Biosimilars Ahead Of Ustekinumab

Amgen has once again touched on its impending expansion into US inflammation/immunology biosimilars, with launches for adalimumab and ustekinumab scheduled for the coming years.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB150101

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel